SCHEMBL2637270

SCHEMBL2637270

Cc1ccncc1OC1CCN(C(=O)C(N)=O)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.51
IKBKB O14920 3/20 0.47
PDE4B Q07343 1/20 0.45
CHUK O15111 1/20 0.44
SMYD3 Q9H7B4 1/20 0.41
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
RBP4 P02753 1/20 0.40
KIT P10721 2/20 0.39
CSF1R P07333 1/20 0.39
PDGFRB P09619 1/20 0.39
DDR1 Q08345 1/20 0.39
EPHX2 P34913 1/20 0.39
SIRT3 Q9NTG7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KMT2A Q03164 1/20 0.39
NAMPT P43490 1/20 0.39
PIM1 P11309 1/20 0.38
ALDH1A1 P00352 2/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2637272 0.84 GPR119 (0.50) GPR119IKBKBCHUKCHRNB2CHRNA4
SCHEMBL2637555 0.79 EPHX2 (0.53) IKBKBPDE4BEPHX2NAMPTALDH1A1
SCHEMBL23021681 0.78 CHRNB2 (0.47) GPR119IKBKBCHUKCHRNB2CHRNA4
SCHEMBL2636901 0.78 GPR119 (0.52) GPR119PDE4BCHRNB2CHRNA4RBP4
SCHEMBL4123852 0.75 IKBKB (0.50) GPR119IKBKBCHUKRBP4KIT
SCHEMBL2636823 0.75 PDE4B (0.45) GPR119PDE4BEPHX2
SCHEMBL19030310 0.74 IKBKB (0.48) GPR119IKBKBCHUKRBP4EPHX2
SCHEMBL2637201 0.72 SCD (0.49) GPR119PDE4BRBP4
SCHEMBL2636562 0.72 CHRM3 (0.47) PDE4BRBP4EPHX2
SCHEMBL2636755 0.72 PDE4B (0.46) PDE4BRBP4EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US claimed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO claimed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US claimed
US-10973810-B2 Methods for the treatment of neurological disorders YUMANITY THERAPEUTICS, INC. (US) 2021-04-13 US disclosed
US-20180193325-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2018-07-12 US disclosed
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10973810-B2 Methods for the treatment of neurological disorders NLN, CLN6, OTC GPR119 4121/4885IKBKB 2165/4885PDE4B 832/4885
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 GPR119 691/4885IKBKB 926/4885PDE4B 1818/4885
US-20180193325-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS NLN, CLN6, OTC GPR119 4121/4885IKBKB 2165/4885PDE4B 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.